Sanofi Consumer Healthcare India share price today

Sanofi Consumer Healthcare India Ltd's share price was ₹3,443.80 at the close on 5 November 2026. It has been falling for 10 weeks. That is 19.2% below its average price over the last 200 trading days. Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 21 weeks running.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Sanofi Consumer Healthcare India Ltd is in stage 4. The phase helps read everything below.

In the last 52 weeks it traded between ₹3,208 and ₹4,868, and at that close it sat 14% of the way up from that low.

Over the last 2.1 years the share price moved −30% while the NIFTY 500 moved −8%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 24 June 2026. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

1. Foreign funds (FIIs) cut their stake for 6 quarters in a row

   From 4.5% to 2.5% of the company by the September 2026 quarter.

2. Indian funds and insurers (DIIs) raised their stake for 5 quarters in a row

   From 16.9% to 18% of the company by the September 2026 quarter.

For July to September 2026 (the quarter ended 30 September 2026), Sanofi Consumer Healthcare India reported revenue of ₹263 crore, up 12.4% from ₹234 crore a year earlier, and a profit of ₹77.0 crore, up 22.2% from ₹63.0 crore.

Sanofi Consumer Healthcare India results: July to September 2026 against a year earlier

The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.

Sanofi Consumer Healthcare India closed at ₹3,443.80 on 5 November 2026, down 25.8% from ₹4,642.60 a year earlier (7 November 2025). Its highest weekly close since September 2024 was ₹5,371.50 on 4 July 2025.

Sanofi Consumer Healthcare India share price: then and now

Weekly closing prices. Each change is the move from that price to the 5 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

119 weekly closes from 13 September 2024 to 5 November 2026.

5 Nov 2026: Sanofi Consumer Healthcare India closed at ₹3,443.80, up 0.0% on the week and down 3.9% on the month. Results for July to September 2026: Revenue up 12.4% and profit up 22.2% on a year earlier.

Earlier

• 19 Jun 2026: ex-date for a dividend of ₹75 a share.

Sanofi Consumer Healthcare India paid ₹75 a share in regular dividends in the 12 months to 5 November 2026 (1 payment), a yield of 2.18% at the ₹3,443.80 close on 5 November 2026. The last was a dividend of ₹75 a share, ex-date 19 June 2026.

Sanofi Consumer Healthcare India dividends since 1 April 2021

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. The record date is the same day as the ex-date for every payment here.

Yes. Sanofi Consumer Healthcare India Ltd paid out 72% of its profit as dividends in FY25, and it paid a dividend in 3 of its last 4 reported years.

From the NSE corporate-actions record, read 5 November 2026.

Sanofi Consumer Healthcare India is on 2 of our India lists: Dividend stocks and Pharma stocks.

Sanofi Consumer Healthcare India Ltd earned ₹77.0 Cr of net profit in the Sep 2026 quarter, +22.2% on the same quarter a year earlier. That is the 6th quarter in a row of profit growth. Full-year FY25 profit was ₹240 Cr. Over 2 years profit has grown 20.6% a year on average. That is 29.3% of the quarter's revenue.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

The same quarter a year earlier earned ₹63.0 Cr.

For the full year, FY25 profit was ₹240 Cr (+0.0% on the year before).

Why profit moved: revenue changed +12.4% on a year earlier and the margin moved +3.0 percentage points. Most of the change came from keeping more of each sale.

On average over the last four quarters, profit changed +30.3% and revenue +24.6%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit.

Sanofi Consumer Healthcare India Ltd reported ₹263 Cr of revenue in the Sep 2026 quarter, +12.4% on the same quarter a year earlier. That is the 6th quarter in a row with growth on the year before. Over 2 years it has grown 25.8% a year on average. The last full year, FY25, came in at ₹878 Cr.

Revenue is everything the company billed its customers in the period.

The last four reported quarters add to ₹979 Cr.

FY25 revenue was ₹878 Cr, +0.0% on the year before.

Recent pace: the last four quarters grew +24.6% on average, against 25.8% a year over the longer run, so this year is growing slower than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +22.5%, against +12.1% a year over the last 8 quarters (accelerating); profit over the last 12 months grew +28.4%, against +16.9% a year (accelerating).

Sanofi Consumer Healthcare India Ltd's operating margin was 39.0% in the Sep 2026 quarter, 3.0 percentage points higher than the same quarter a year ago. Across 4 years it has been between 35.0% and 39.0%. The latest quarter is within that range.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed +2.3 percentage points on the year while gross margin changed +1.9 points. So the gain came mostly from the gross margin, which means input costs and prices charged.

Over the last 3 years, 105% of Sanofi Consumer Healthcare India Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY25 it brought in ₹175 Cr of operating cash against ₹240 Cr of profit. After ₹18.0 Cr of spending on assets, ₹157 Cr was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 105% of profit came in as cash: the cash cycle got 125 days shorter between FY23 and FY25, so cash that used to wait in the business now arrives sooner.

What to look at next: the bigger use of cash is spending on new assets, at 2.8× depreciation over three years. The next section checks what that spending is building.

Sanofi Consumer Healthcare India Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was −16 days in FY25, down from 109 days in FY23. It spent ₹44.0 Cr on assets over the last 2 years. Customers take 12 days to pay, and stock sits for 98 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY25 sales of ₹878 Cr, each day of that cycle ties up about ₹2.4 Cr, so roughly −₹38.0 Cr is tied up in the business at any time.

FY25: customers took 12 days to pay and stock sat for 98 days, about 3.2 months of sales sitting as stock, for a full cycle of −16 days, shorter than FY23's 109.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 98 days. Customers pay about 12 days after that. Suppliers are paid at 126 days. Together that makes the −16-day cycle.

Spending on assets: ₹44.0 Cr over the last 2 years, against ₹16.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹0.0 Cr (FY25): assets paid for that are not earning yet.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

Sanofi Consumer Healthcare India Ltd's P/E is 28.3×, about the lowest it has ever been. Its usual P/E (the middle reading) is 48.6×, over 2.1 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

Why the multiple is where it is: over the past year earnings per share moved +0.0% while the price moved −25.8%. Earnings did better than the price, which pulled the multiple down within its own range.

In short: the multiple is low against its own past, so the earnings trend underneath matters more than the multiple.

Sanofi Consumer Healthcare India Ltd's business is giving mixed signals. Growth is slowing from a very fast pace: revenue growth has eased from +46.8% at its peak to +12.4% (from single-quarter figures), but the business is still expanding, with ROCE rising at 112.6%. This is based on 11 quarters of 3 measures, with some gaps.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

Why it matters: when the lines disagree, each line above matters more than any single label.

One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result.

This reading has some gaps: at least one line is short, or the return line is not the quarterly series, so treat it with a little more caution.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the share price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

Sanofi Consumer Healthcare India Ltd earned a ROCE of 90% in FY25. Its return on capital used (ROIC) is 651.3 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 27.3% net margin and 1.61× asset turnover (sales divided by assets).

Return on capital employed (ROCE) is the profit the whole business earns on all the money in it, from shareholders and lenders together. It is the best single test of whether growth adds value or just size.

Why the return is what it is (FY25): a 27.3% net margin × 1.61× asset turnover × 1.42× leverage (assets divided by equity) ≈ 62.4% on equity. The margin does most of the work; borrowing plays a small part, so this return is earned, not borrowed.

The key test, return on capital used minus the cost of capital: 663.3% − 12.0% = +651.3 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. A gap this wide means each rupee put back into the business creates more than a rupee of value.

Sanofi Consumer Healthcare India Ltd has total debt of ₹21.0 Cr against shareholder equity of ₹348 Cr as of Sep 2026, so its debt is 0.06× its equity, which is very little. Year by year, that ratio went from 0.07 in FY25 to 0.07 in FY26. So the returns on this page come from the business, not from borrowed money.

Debt-to-equity shows how much of the business is paid for with borrowed money. Lower is safer, and the direction matters as much as the level.

Promoters raised their stake in Sanofi Consumer Healthcare India Ltd by 10.9 percentage points over 8 quarters, the biggest change among its owners. Promoters now own 71.3% of the company. Domestic institutions moved −5.8 points over the same period, to 18.0%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings.

Who owns the company each quarter: promoters (the founders or controlling owners), foreign institutions, domestic institutions such as mutual funds, and the public. When people close to the business steadily raise their stake, that is worth noticing; a quiet list is also an answer.

Over the last two years: Promoters: +10.9 points over 8 quarters, to 71.3%; Domestic institutions: −5.8 points over 8 quarters, to 18.0%; Foreign institutions: −2.7 points over 8 quarters, to 2.5%.

Why the owners changed: promoters drove it (+10.9 points), with the other side taken by domestic institutions (−5.8 points). They raised their stake step by step.

For Sanofi Consumer Healthcare India Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date.

The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.

59.6 out of 100, rank 3 of 8 in Pharma - MNC bulk Drugs, with 93% of the evidence available.

Sanofi Consumer Healthcare India Ltd scores 59.6 out of 100 against the 8 companies it is compared with in Pharma - MNC bulk Drugs, ranking 3. Earnings are strong; relative strength in its sector is -19.5% and the one-year return is -28.9%.

The four parts add up to the total exactly: 24 + 21.5 + 14.1 + 0 = 59.6. This is the same number shown on the industry page; it is worked out once for the whole group and read here.

What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector.

Sanofi Consumer Healthcare India ranks 3 of 8 Pharma - MNC bulk Drugs companies on the 4-Factor Sector Score, with 59.6 out of 100.

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read.

The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section.

Related companies: Pharma - MNC bulk Drugs, all 8 compared on one page.

Sanofi Consumer Healthcare India is the 6th largest of 8 Pharma - MNC bulk Drugs companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Glaxosmithkline Pharmaceuticals, Pfizer, Astrazeneca Pharma India and Procter & Gamble Health. Just below it: Sanofi India and Novartis India.

Pharma - MNC bulk Drugs companies close in size

2. Glaxosmithkline Pharmaceuticals Ltd ₹42,255 crore
3. Pfizer Ltd ₹17,655 crore
4. Astrazeneca Pharma India Ltd ₹15,911 crore
5. Procter & Gamble Health Ltd ₹9,413 crore
6. Sanofi Consumer Healthcare India Ltd ₹7,925 crore
7. Sanofi India Ltd ₹7,775 crore
8. Novartis India Ltd ₹4,179 crore

All 8 Pharma - MNC bulk Drugs companies, largest first

Companies close in size in other industries

656. Knowledge Marine & Engineering Works Ltd ₹7,977 crore · Shipping
657. Sudarshan Chemical Industries Ltd ₹7,930 crore · Dyes & Pigments
658. Sanofi Consumer Healthcare India Ltd ₹7,925 crore
659. Standard Engineering Technology Ltd ₹7,913 crore · Engineering - Heavy - Glass - lined Equipment
660. KRBL Ltd ₹7,898 crore · FMCG - Rice

Sector Alpha, written by code from the published numbers. Data as of 5 November 2026.

Every chart on this page is drawn by code from the published figures, with no forecasts and no price opinions.

See the plain-text version of this page.